We are pleased to announce the start of the PRIME-HF trial (Predischarge Initiation of Ivabradine in the Management of Heart Failure). PRIME-HF is a pragmatic trial that will test the efficacy of initiation of ivabradine prior to discharge from a hospitalization for acute HF compared with usual care. Key endpoints include quality of life, heart rate, beta-blocker use and clinical outcomes through 6 mos. It is a 450-patient study that will begin enrolling soon. Of the 50 sites, we are targeting at >20 DUCCS sites so we can revive the DUCCS vs. SWANs (sites without a name) competition.
We see PRIME-HF as a critical trial to build upon the prior research successes of the DUCCS’ consortium and lay the foundation for future studies.
Please contact Megan Honig if you are interested in participating as a site in PRIME-HF.